Table 3.

Univariate hazards for transplantation outcomes in patients with AML, according to different KIR-based donor grouping tools

		n	Survival	P	EFS	P	Relapse	P	Treatment-related mortality	P	Acute GVHD (100 d)	P
KIR3DL1 Inhibition
	KIR3DL1-Weak Inhibiting	46	Reference		Reference		Reference		Reference		Reference
	KIR3DL1-Noninteracting	92	1.84 (0.98-3.43)	.058	2.16 (1.21-3.84)	.009	3.03 (1.41-6.5)	.004	1.13 (0.44-2.88)	.795	1.17 (0.65-2.11)	.604
	KIR3DL1-Strong Inhibiting	39	1.55 (0.76-3.16)	.231	1.81 (0.94-3.49)	.077	1.98 (0.82-4.79)	.128	1.63 (0.61-4.38)	.334	1.58 (0.81-3.07)	.18
KIR3DL1, 2 groups
	KIR3DL1-Weak Inhibiting	46	Reference		Reference		Reference		Reference		Reference
	KIR3DL1-Noninteracting or Strong Inhibiting	131	1.74 (0.95-3.17)	.073	2.04 (1.17-3.56)	.012	2.68 (1.27-5.64)	.01	1.3 (0.55-3.07)	.546	1.29 (0.74-2.25)	.376
KIR2DS1
	KIR2DS1-/HLA-C1+	126	Reference		Reference		Reference		Reference		Reference
	KIR2DS1+/HLA-C1+	108	0.85 (0.53-1.36)	.495	1.07 (0.7-1.62)	.758	1.19 (0.72-1.97)	.506	0.85 (0.4-1.8)	.667	1.1 (0.69-1.75)	.702
Centromeric haplotype B content
	CenAA	88	Reference		Reference		Reference		Reference		Reference
	CenAB	75	0.67 (0.41-1.1)	.115	0.67 (0.43-1.05)	.078	0.66 (0.39-1.14)	.137	0.69 (0.32-1.5)	.347	0.79 (0.48-1.3)	.354
	CenBB	14	1.07 (0.45-2.53)	.879	1.01 (0.46-2.24)	.976	1.04 (0.41-2.67)	.931	0.94 (0.22-4.14)	.938	0.76 (0.3-1.93)	.562
Combined ranking schemas
	KIR advantageous	87	Reference		Reference		Reference		Reference		Reference
	No ranking	34	1.5 (0.8-2.79)	.206	1.23 (0.7-2.17)	.475	0.96 (0.47-1.97)	.913	2.04 (0.78-5.38)	.148	0.61 (0.29-1.28)	.191
	KIR disadvantageous	56	1.33 (0.79-2.24)	.29	1.14 (0.71-1.83)	.578	0.99 (0.56-1.74)	.965	1.61 (0.68-3.79)	.278	1.18 (0.71-1.96)	.527